Greenwich Biotech Ventures

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company's lead product candidate, GP2, is a 9-amino acid peptide derived from the HER2/neu protein, which is expressed in several common cancers. Greenwich LifeSciences is currently advancing its Phase 3 clinical trial, FLAMINGO-01, which evaluates GP2 in patients who are HER2/neu 3+ and have completed prior surgery and trastuzumab-based therapy. The company's mission is to provide a safe and effective treatment to eliminate the risk of cancer recurrence in survivors. Headquartered in Stafford, Texas, the company is publicly traded on the Nasdaq under the symbol GLSI.